ArticleScientific reports2026
Lipodystrophy and associated factors among patients with diabetes receiving insulin therapy: a multicenter study in Ethiopia.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipodystrophy alters insulin absorption, potentially leading to unpredictable hypoglycemia and inadequate glycemic control. Although the problem is long known, it continues to persist and remains neglected, particularly among diabetic patients in developing countries. This study evaluated its magnitude and different contributing factors. This study aimed to assess the prevalence of lipodystrophy, and their contributing factors among patients receiving insulin therapy in three selected hospitals of Northwest Ethiopia. A cross-sectional study was conducted from April 5 to September 30, 2023, at the University of Gondar, Tibebe ghion and Debre Markos Comprehensive Specialized Hospitals. Standardized physical examinations were used to assess the presence of lipodystrophy and data on demographic characteristics, clinical characteristics, and drug related characteristics were used for analysis. Logistic regression was used to identify factors associated with lipodystrophy. Among participants, 54.3% had type 1 diabetes mellitus. The larger part of study participants (71.5%) reported having diabetes mellitus for over five years. Insulin-induced lipodystrophy was observed in 225 cases (53.1%). Grade 2 lipohypertrophy was the most common type (52.7%), marked by significant fat thickening, while Grade 3 lipoatrophy was rare (1.8%). The abdomen was the most affected injection site (36.5%), followed by multiple sites (32%). Failure to rotate (AOR = 1.8, p-value 0.004), needle reuse, glycemic control (AOR = 2.15, p-value 0.019), and insulin dosage per kg (AOR = 2.1, p-value 0.001) were found to have an association with lipodystrophy. The study revealed a high prevalence of lipodystrophy among diabetic patients using insulin injections, highlighting the need for greater attention to ensure comprehensive diabetes care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.